Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

PURPOSE: The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of...

Descripción completa

Detalles Bibliográficos
Autores principales: Spigel, David R., Faivre-Finn, Corinne, Gray, Jhanelle E., Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F., Garassino, Marina C., Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H., Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C., Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015199/
https://www.ncbi.nlm.nih.gov/pubmed/35108059
http://dx.doi.org/10.1200/JCO.21.01308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015199/
https://www.ncbi.nlm.nih.gov/pubmed/35108059
http://dx.doi.org/10.1200/JCO.21.01308

Ejemplares similares